clinical trial · NCT05987423
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
Hoffmann-La Roche·phase3·active not recruiting·n = 131
Thyroid Eye DiseaseTEDSatralizumabPlacebo
brief summary
The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous (SC) satralizumab, a recombinant, humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, in participants with thyroid eye disease (TED).
started
Oct 26, 2023
primary completion
Jul 8, 2025
completion
Jul 1, 2026
last updated
Feb 3, 2026
official title
A Phase III, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Moderate-to-Severe Thyroid Eye Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol